Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer

Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation

(2022) Shi-Suo Du et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

(2022) Jonathan D Schoenfeld et al.   LANCET ONCOLOGY

cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy

(2022) Zi-Jie Long et al.   MOLECULAR THERAPY

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

(2022) Meng Yuan et al.   Oxidative Medicine and Cellular Longevity

Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer

(2022) Xiaohua Jie et al.   Journal for ImmunoTherapy of Cancer

Type I interferon-mediated tumor immunity and its role in immunotherapy

(2022) Renren Yu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

(2022) Alex K. Bryant et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway

(2022) Jessica Marinello et al.   BRITISH JOURNAL OF CANCER

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

(2021) Jun-Yan Li et al.   Molecular Cancer

Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors

(2021) E. Reijmen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

(2021) Sandra Demaria et al.   Journal for ImmunoTherapy of Cancer

Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma

(2021) Yan Huang et al.   RADIOTHERAPY AND ONCOLOGY

Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

(2021) Fernanda G Herrera et al.   Cancer Discovery

Monitoring Early Glycolytic Flux Alterations Following Radiotherapy in Cancer and Immune Cells: Hyperpolarized Carbon-13 Magnetic Resonance Imaging Study

(2021) Ying-Chieh Lai et al.   Metabolites

Radiotherapy and immunotherapy for cancer: From "systemic" to "multi-site"

(2020) Ainhoa Arina et al.   CLINICAL CANCER RESEARCH

Tissue-resident memory T cells in breast cancer control and immunotherapy responses

(2020) Ann Byrne et al.   Nature Reviews Clinical Oncology

Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients

(2020) Limei Yin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

(2020) Shaochuan Liu et al.   Cell Death & Disease

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

(2020) Hailong Sheng et al.   Journal for ImmunoTherapy of Cancer

Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling

(2020) Alice Lepelley et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Bip inhibition in glioma stem cells promotes radiation-induced immunogenic cell death

(2020) Wei Yang et al.   Cell Death & Disease

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

(2020) Willemijn S M E Theelen et al.   Lancet Respiratory Medicine

Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer

(2019) Sha Zhao et al.   Cancer Immunology Research

Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer

(2019) Xuefei Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

(2019) Willemijn S. M. E. Theelen et al.   JAMA Oncology

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Targeting DNA repair in cancer: current state and novel approaches

(2019) Apostolos Klinakis et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma

(2019) Junbin Liao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy

(2018) Ariel E. Marciscano et al.   CLINICAL CANCER RESEARCH

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1

(2018) Binyan Lin et al.   GENE

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers

(2018) Le Ying et al.   OncoImmunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage

(2018) Gillian Dunphy et al.   MOLECULAR CELL

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

(2018) Jianfeng Shen et al.   CANCER RESEARCH

Mitotic progression following DNA damage enables pattern recognition within micronuclei

(2017) Shane M. Harding et al.   NATURE

Cytoplasmic chromatin triggers inflammation in senescence and cancer

(2017) Zhixun Dou et al.   NATURE

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

(2017) Han Zhao et al.   CELLULAR ONCOLOGY

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Activation of STING requires palmitoylation at the Golgi

(2016) Kojiro Mukai et al.   Nature Communications

Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells

(2015) Hui Gao et al.   CANCER LETTERS

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy

(2014) M.T. Dillon et al.   CLINICAL ONCOLOGY

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Inflammation-driven carcinogenesis is mediated through STING

(2014) Jeonghyun Ahn et al.   Nature Communications

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

(2013) Felix Klug et al.   CANCER CELL

Toxicity of Concurrent Radiochemotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the Literature

(2013) Caro C. Koning et al.   Clinical Lung Cancer

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Double-strand break repair: 53BP1 comes into focus

(2013) Stephanie Panier et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells

(2009) Kenji Chamoto et al.   CANCER SCIENCE